Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adeno-associated virus serotype 4 (AAV4) is a viral vector platform utilized in gene therapy to deliver therapeutic genetic material to specific tissues. Derived from the Parvoviridae family, AAV4 is characterized by its unique cellular tropism, which is mediated by binding to O-linked sialic acid on the surface of target cells. It has shown particular efficiency in transducing the ependymal lining of the ventricles in the central nervous system and the retinal pigmented epithelium in the eye. In comparative studies for cardiac gene delivery, AAV4 has demonstrated lower transduction efficiency in cardiomyocytes compared to other serotypes like AAV1, AAV6, or AAV9. As a replication-deficient vector, it is engineered to provide long-term transgene expression with a low immunogenic profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adeno-associated virus serotype 4.